Bern Human Organoid-Study to Study Host-microbe Interaction

Microbiota Clinical Trial

— humorg  

Official title:

Establishment of Human Organoid Lines as a Tool to Dissect Molecular Pathways of Host-microbiota Interactions

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05323357
• Other study ID #: 2021-01865
• Status: Recruiting
• Start date: March 31, 2022
• Est. completion date: March 30, 2026

Study information

• Verified date: May 2023
• Source: University Hospital Inselspital, Berne
• Contact: Bauchzentrum
• Phone: +41 31 632 59 00
• Email: bauchzentrum[@]insel.ch
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The human body inhabits a complex consortium of different microbes which together form the microbiota. Virtually every surface of the human body is colonized by a distinct microbiota, forming complex communities. An increasing number of research results indicates that changes in the microbiota can have vast effects on the health of its host. Most studies investigating the microbiota were conducted on animals, as many interventions and investigations cannot be performed on humans due to ethical considerations. This raises the question if findings from experimental studies are translational and can benefit patients. That becomes especially apparent when trying to dissect molecular mechanisms involved in this fine-tuned interplay between nutrients, the microbiota, and its host. By establishing human organoid cultures from the large and small intestine that can be exposed to microbes and/or microbial products with subsequent transcriptomic, epigenetic and immunological analysis, the investigators aim to generate findings with high translational potential with new insights into the complex interaction of the microbiota, the host and its immune system.

Description:

- Data obtained from participants will be recorded in the database Redcap to ensure high-quality data recording - Establishment of human organoid cultures are standardized by published protocols (Pleguezuelos-Manzano et al. 2020)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: March 30, 2026
• Est. primary completion date: March 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Signed informed consent
• Indication for upper or lower endoscopic procedure
• Ability to understand and follow study procedures and understand informed consent
• Age 18-80 years
• Negative pregnancy test result prior to study enrollment of female study participants (test will be performed prior to enrollment)
• BMI between 18.5 and 30 kg/m2

Exclusion Criteria:

• Disease known to chronically affect gut microbiota, gut epithelium or gut-associated immune system, namely inflammatory bowel disease, diverticulitis, microscopic colitis, liver cirrhosis, malignancy within the digestive tract, systemic sclerosis, coeliac disease, common-variable immunodeficiency, diabetes mellitus
• Medication with immunosuppressants (e.g. corticoids, biological therapy)
• Current diagnosis of a hematological disorder (e.g. anemia with hemoglobin <7 g/dl, leukemia) or any other absolute contraindication for blood draw
• Women who are pregnant
• Serious coagulation disorder, relevant thrombocytopenia (<50'000/ul), double platelet-inhibition, oral anticoagulation (ASS therapy is possible)
• Known or suspected non-compliance, drug, or alcohol abuse
• Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant
• Previous enrolment into the current study
• Enrolment of the investigator, his/her family members, employees, and other dependent persons
• Inability or unwillingness to provide blood samples and tissue samples (biopsies)
• Participants taking oral anticoagulant or with bleeding disorders who would be at much higher risk of bleeding after biopsy samples or who are contraindicated for an endoscopic examination
• Patients unable to give informed consent
• Patients that have been under antibiotic therapy in the last 4 weeks
• Participation in other clinical study interfering with study procedures
• Potential study participants that wish not to be informed about random results acquired during the study (e.g., during endoscopy or genetic analysis) relevant for their health and for prevention of diseases

Related Conditions & MeSH terms

• Allergy and Immunology
• Microbiota
• Organoids

Locations

Country	Name	City	State
Switzerland	Inselspital, University Hospital Bern	Bern

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital Inselspital, Berne	University of Bern

Country where clinical trial is conducted

Switzerland, 

References & Publications (1)

Pleguezuelos-Manzano C, Puschhof J, van den Brink S, Geurts V, Beumer J, Clevers H. Establishment and Culture of Human Intestinal Organoids Derived from Adult Stem Cells. Curr Protoc Immunol. 2020 Sep;130(1):e106. doi: 10.1002/cpim.106. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of changes in the transcriptomic profile of epithelial cells before and after organoid culture	Assessment of changes in the transcriptomic profile of epithelial cells before and after organoid culture is established by RNA-sequencing and quantitative polymerase chain reaction (qPCR)	3 Years
Primary	Assessment of changes in the epigenome of epithelial cells before and after organoid culture	Assessment of changes in the epigenome of epithelial cells before and after organoid culture is established by whole genome bisulphite sequencing and chromatin immunoprecipitation sequencing	3 Years
Primary	Transcriptomic and Epigenomic Landscape of host-microbiota Interaction	Determining effects of microbial-derived metabolites on the transcriptomic and epigenomic landscape of human organoids treated with the respective metabolite	3 Years
Primary	Host-Microbiota interaction - Stem cell maintenance and Cell Differentiation	Determining effects of microbial-derived metabolites on epithelial cell differentiation and stem cell maintenance	3 Years
Secondary	3D-to-2D Transwell System	Establishing a method to transform human organoid culture into a 2-dimensional trans-well system which allows transportation studies, characterization of epithelial integrity and other downstream analysis	3 Years
Secondary	Gut-on-a-chip	Applying 2-dimensional trans-well system to a gut-on-a-chip set-up in collaboration with the Artorg Center at the University of Bern	3 Years

External Links

•   Pleguezuelos-Manzano C et al. 2020